prioriti review week decemb
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
neurocrin ingrezza fail pediatr tourett phase studi manag emphas believ trial design conduct
pow ere ell point lack efficaci fail result follow -up call manag recommend remov
tourett syndrom program model estim go forw ard thought tourett gold miss
gilead select roch pharma ceo daniel oday next ceo gregg alton ill serv interim ceo januari hen
john milligan step dow nsuntil mr day schedul start march mr oday join roch serv varieti
leadership role includ head corpor plan japan presid roch molecular
diagnost thought potenti gilead ceo hire
biohaven report rimegep posit interim long-term safeti data extern independ panel liver expert identifi
liver safeti signal includ particip near-daili treatment doses/month rate elev laboratori liver
abnorm serum alt ast uln compar placebo rimegep also demonstr sign efficaci
prevent treatment ith particip ith migrain days/month experienc reduct headach days/month follow ing
month intermitt dose thought rimegep safeti data
jnj tremfya superior novarti cosentyx studi plaqu psoriasi eclips particip treat ith
tremfya achiev least improv baselin pasi score eek vs treat ith cosentyx
public abstract last eek impli result effect size ever clear detail eclips
data impress superior thought eclips abstract titl
fda accept ind bioxcel acut agit bioxcel intend evalu sublingu formul
dexmedetomidin dex pk/pd/ safeti phase human volunt ith data expect enabl start subsequ
registr studi senil dementia alzheim type sdat schizophrenia ind approv show
bausch acquir synergi pharma assetsinclud ironwood competitor trulanc cash deal includ
lupin receiv tent fda approv gener biogen tecfidera approv includ tw dose mg
gritston advanc anti-solid tumor bispecif program compani intend leverag ai platform edg identifi high
prioriti antigen gritston focus antibodi bind tumor-specif peptide-hla complex hlap hich structur
similar t-cell receptor bind program ill led new ly appoint vice-president antibodi therapeut jonah rainey phd
 thought bispecif program progress
bristol collabor microbiom focus vedanta bioscienc clinic trial collabor ill evalu opdivo
combin ith vendanta microbi consortium develop activ cytotox cellsin advanc metastat
cancer per agreement bristol ill make equiti invest vedanta ith latter retain control
collabor entera inflammatori diseas entera technolog platform enabl oral deliveri
larg molecul via small molecul enhanc absorpt anoth protect larg molecul digest per
term agreement ill provid small up-front fee financi support pre-clin develop three
program ith entera elig receiv mid-singl digit tier royalti ill assum clinic
develop manufactur commerci
merck biolinerx initi tripl combin pancreat cancer trial phase patient
 ill evalu safeti toler keytruda chemotherapi small peptid antagonist observ
increas t-cell infiltr tumor data expect previous develop also phase
develop aml
announc collabor magellan rx manag first value-bas collabor ith pbm ill
focu initi osteoporosi migrain market osteoporosi project ill follow ith osteoporosi patient ho
fractur increas level follow treatment save long-term treatment cost migrain project ill aim
increas treatment migrain suffer ith non-opioid educ payer employ cost lost product
fda grant track design baricitinib system lupu erythematosu sle phase proof-of-concept studi
demonstr dose qd provid improv patient adequ control current soc
treatment publish result see link tw phase brave brave ii underw ay ith data expect
celgen licens two trinket candid dragonfli therapeut celgen ill pay up-front tw
immunotherapi candid addit potenti mileston royalti last month compani expand strateg
collabor solid tumor leverag dragonfli trinket tri-specif nk cell engag therapi technolog platform
end collabor appli genet follow neg xlrp data appli genet phase
gene therapi x-link retinoschisi xlr reveal sign clinic activ month prompt end
partnership xlr x-link retin pigmentosa xlrp
health canada approv market author vertex orkambi patient year year old label extens
approv fda august applic submit ema chmp adopt posit opinion novemb
merck announc acquisit antelliq group antelliq privat held anim health compani focus digit anim
identif traceabl monitor merck ill pay cash share antelliq assum debt hich plan
pay transact close
lilli expand collabor evid access smartphon data platform agreement allow lilli access patient
behavior data smartphon connect sensor term deal undisclos evid andromeda platform includ
data collect health track app ith million user
amgen nplate approv pediatr immun thrombocytopenia applic grant prioriti review design label
expans includ patient one year age older ho immun thrombocytopenia least month
insuffici respons corticosteroid immunoglobulin splenectomi
proprietari research past week
 model catalyst updat
neurocrin bioscienc move beyond ts data
updat model see link
client ask
investor ask follow ing topic phone call email in-person market meet
updat view neurocrin follow t-forc gold failur sell-off share understand
view present good buy opportun ingrezza remain high-grow th asset td compound-annual-growth-rate ith peak
potenti manag emphas us higher strateg prioriti maxim sale hen orilissa
econom go ad ingrezza think becom bigger part stori
highlight earn pow er next year ith sever upsid driver model dont includ
poc data opicapon potenti label expans orilissa ingrezza see upsid make
neurocrin still high-qual grow th stori smid cap biotech
takeaway gilead select daniel oday next ceo view mr oday proven biopharma
execut ith good investor visibl ho could augment futur strateg direct gilead includ oncolog inflamm
versu histor focu virolog hiv hcv ed also argu mr oday like aggress
deal biz-dev front hich strategi investor favor ould help divers core hiv franchis overal
think mr oday could immedi posit impact gilead given broad divers experi biopharma
although dont expect broad discuss specif strateg vision perhap call
reaction reuter articl talc powder share weak view eak share
market cap loss overreact potenti litig concern talc overhang stock quit
time main concern investor hether could face ith crimin charg dow road light alleg
made recent reuter report link hile expect on-going litig regard compani babi pow der franchis
remain overhang share near- long-term think stori risk materi chang view
even inform reuter articl meritw hich think unlik especi given recent fda report august
could presum take mani year play legal set talc risk ms overdon us
watch week ahead
clinic trial read-out regulatori event expect near-term
achn pnh phase interim data healthi volunt phase interim data expect
phase data expect
phase data tnbc expect merkel cell carcinoma pdufa date
let us know question comment geoff jason olivia greg scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
